scholarly journals Patients with only 1 positive hormone receptor have increased locoregional recurrence compared with patients with estrogen receptor-positive progesterone receptor-positive disease in very early stage breast cancer

Cancer ◽  
2010 ◽  
Vol 117 (8) ◽  
pp. 1595-1601 ◽  
Author(s):  
Jeffrey M. Albert ◽  
Ana M. Gonzalez-Angulo ◽  
Merih Guray ◽  
Aysegul Sahin ◽  
Welela Tereffe ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Progesterone Receptor ◽  
Hormone Receptor ◽  
Locoregional Recurrence ◽  
Early Stage ◽  
Early Stage Breast Cancer ◽  
Estrogen Receptor Positive

MDM2 amplification is an independent prognostic feature of node-negative, estrogen receptor-positive early-stage breast cancer

2011 ◽  
Vol 8 (2) ◽  
pp. 53-60 ◽  
Author(s):  
Matthias Choschzick ◽  
Uwe Heilenkötter ◽  
Annette Lebeau ◽  
Fritz Jaenicke ◽  
Luigi Terracciano ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Early Stage ◽  
Early Stage Breast Cancer ◽  
Node Negative ◽  
Estrogen Receptor Positive ◽  
Prognostic Feature ◽  
Mdm2 Amplification

Prospective study of the impact of using the 21-gene recurrence score assay on clinical decision making in women with estrogen receptor-positive, HER2-negative, early-stage breast cancer in France.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 568-568 ◽  
Author(s):  
Joseph Gligorov ◽  
Xavier B. Pivot ◽  
Herve L. Naman ◽  
William Jacot ◽  
Dominique Spaeth ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Early Stage ◽  
Recurrence Score ◽  
Oncotype Dx ◽  
Early Stage Breast Cancer ◽  
Treatment Recommendation ◽  
Endocrine Treatment ◽  
Estrogen Receptor Positive ◽  
The Impact

568^ Background: The 21-gene Oncotype DX Recurrence Score (RS) is a validated assay to help inform the appropriate treatment of estrogen receptor-positive (ER+), early stage breast cancer in the adjuvant setting. Treatment traditions regarding choice of adjuvant treatment vary significantly in different countries. This prospective multicenter study is the first to assess the impact of using the Oncotype DX assay in the French clinical setting. Methods: A total of 100 consecutive patients with ER+, HER2-negative, node negative or pN1 (mi) breast cancer were enrolled. Overall treatment recommendation change, change from chemoendocrine to endocrine alone and change from endocrine alone to chemoendocrine treatment were recorded. Medical oncologists completed questionnaires regarding their confidence in their recommendation before and after knowing the patient’s RS. A preliminary analysis was conducted on the first 92 evaluable patients with data available at the time of abstract submission. Final data will be presented at the meeting. Results: Prior to Oncotype DX 49% of patients were recommended chemoendocrine treatment and 51% endocrine treatment alone. After having the RS, 26% were recommended chemoendocrine treatment and 74% endocrine treatment alone. The overall reduction in chemotherapy recommendation from 49% to 26% was significant (p<0.001). Of patients originally recommended chemoendocrine treatment, 58% were changed to endocrine treatment alone after having the RS. Of patients originally recommended endocrine treatment, 11% were changed to chemoendocrine treatment after receiving the RS. There was a significant improvement in physician confidence in treatment recommendations (p=0.002) when using Oncotype DX. Conclusions: These are the first prospective data regarding the impact of using Oncotype DX in France. Using Oncotype DX was associated with a significant change in treatment decisions and an overall reduction in chemotherapy use. The data are consistent with those presented from Germany, Spain, the UK and the US.

scholarly journals Comparison between Oncotype DX test and standard prognostic criteria in estrogen receptor positive early-stage breast cancer

2011 ◽  
Vol 9 (3) ◽  
pp. 354-358 ◽  
Author(s):  
Marcelo Roberto Pereira Freitas ◽  
Sergio Daniel Simon
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Early Stage ◽  
Recurrence Score ◽  
Oncotype Dx ◽  
Early Stage Breast Cancer ◽  
Exact Test ◽  
Prognostic Criteria ◽  
Estrogen Receptor Positive ◽  
Kappa Value

ABSTRACT Objective: To compare the prognosis estimated by standard prognostic criteria versus the prognosis estimated by the Oncotype DX. Methods: A retrospective study was performed on 22 patients with positive estrogen receptor, early-stage breast cancer who had an Oncotype DX recurrence score available. Results: Kappa value between Oncotype DX and standard prognostic criteria was: Adjuvant! (K = 0.091), Adjuvant! (Transbig) (K = 0.182) and National Comprehensive Cancer Network (K = 0.091). The Fisher's exact test did not show correlation between Oncotype and standard prognostic criteria. Conclusion: Standard prognostic criteria showed no correlation with Oncotype DX.

Sign in / Sign up

Export Citation Format

Share Document